Shlomo Melmed, MB, ChB, FRCP, MACP
As Dean, Executive VP and Professor of Medicine at Cedars-Sinai Medical Center in Los Angeles, Dr. Melmed has coupled his institutional leadership in building renowned academic programs with a sustained Impact on the practice of pituitary medicine by his endocrine leadership, educational initiatives and major translational discoveries in pathophysiology and therapy of pituitary disease.
Consistently funded by NIH since 1980, his lab has elucidated mechanisms for pituitary growth factor regulation, tumorigenesis, growth hormone action, discovered mechanisms underlying regulation of disordered ACTH and GH production, and identified novel molecules for pituitary tumor therapy. In landmark publications, he described ectopic GH acromegaly syndrome, discovered pituitary tumor transforming gene, and pioneered receptor subtype-specific analogs for neuroendocrine tumor therapy. He demonstrated receptor subtype-specific somatostatin analogs selectively targeting human pituitary hormone production, recognized the utility of these subtype-specific analogs to enhance pituitary tumor therapy, leading to a new generation of pharmacologic agents for pituitary tumor treatment. He was global PI for the US registration trials for two of the approved somatostatin analogs. He developed rodent and zebrafish models of pituitary tumorigenesis, faithfully recapitulating human disease to identify targeted small molecule inhibitors for aggressive prolactinomas and Cushing disease. Both these discoveries have led to investigator-initiated, federally-funded prospective clinical trials.
He has co-authored acromegaly consensus guidelines, three Endocrine Society pituitary medicine guidelines, and his NIH-funded training program has nurtured over 75 doctoral and post-doctoral trainees. He is a global leader of pituitary medicine education as pituitary editor of the major endocrinology textbook used worldwide, Williams, and pituitary co-author for Harrisons textbook. As past editor-in-chief of Endocrinology, and currently of Pituitary, he exemplifies an international pituitary scholar and leader. He has served on NIH study sections, is Past President of the International Society of Endocrinology and of the Pituitary Society, and has received prestigious awards from the Endocrine Society, UK Society of Endocrinology, the Fondation Ipsen and the Royal Society of Medicine. He is a director of the California Institute of Regenerative Medicine and of the California Life Sciences Association.
His exemplary publications in the very highest quality basic and clinical journals reflect a duality of outstanding basic and clinical creativity underscoring his standing as a leader of pituitary medicine and discovery. Few physician-scientists have contributed more to our fundamental and clinical understanding of pituitary tumor biology as it is applied to the diagnosis and treatment of pituitary disease.